Phase I Study of MT1011 Injection in Healthy Subjects

NCT07024160 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation

Interventions

DRUG: MT1011
DRUG: Placebo

Sponsor

Shaanxi Micot Pharmaceutical Technology Co., Ltd.